The life sciences team at Penningtons Manches will be attending the Biotrinity Conference held this year on the 9 and 10 May in London. One of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK, BioTrinity offers unique access to global life science investors, big pharma executives and innovative CEOs of emerging R&D companies seeking to make deals and grow their networks.
Partners Jim Kinnier Wilson, Chris Shelley and Will Axtell and senior associates Rachel Bradley, Katya Ascher and Bill Smith will be available to speak about the firm’s life sciences practice at stand number 15.
It has been a successful few months for the team following its recognition in the Corporate Intl Global Awards for ‘Life Sciences Law Firm of the Year in England’ for the fifth consecutive year, as well as the ‘Life Sciences Law Firm of the Year in England’ in the 2016 Global Law Experts’ awards in the Client Choice category. The team has recently advised Oxford University spin-out and precision cancer medicines company, Celleron Therapeutics Limited, on its substantial financing round with South Korean investors. Earlier this year, Penningtons Manches advised NeRRe Therapeutics on its £23 million Series B funding round involving leading transatlantic life sciences investors.